Drug Trial Radar · NCT00811941
Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence
Last checked: Nov 20, 2026Latest source record: Aug 7, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
665
Actual
Start
Mar 2009
Primary completion
Nov 2010
Study completion Nov 2010
Sponsor
- Lead sponsor
- H. Lundbeck A/SIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is long-term safety, tolerability and efficacy of nalmefene in patients with alcohol dependence.
Conditions
- Alcohol Dependence
Interventions
PlaceboDrug
as-needed use, tablets, orally, 52 weeks
NalmefeneDrug
18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With Adverse Events (AEs)Time frame: Serious Adverse Events: 52 weeks and a safety follow-up (visit/telephone call) scheduled for 4 weeks after completion of the study or after withdrawal from the study. Other Adverse Events: 52 weeks.
- Percentage of Patients Who Withdrew Due to Intolerance to TreatmentTime frame: Baseline to Week 52
- Change From Baseline in the Monthly Number of Heavy Drinking Days (HDDs)Time frame: Baseline and Month 6
- Change From Baseline in the Monthly Total Alcohol Consumption (TAC)Time frame: Baseline and Month 6
Locations
60 sites in 10 countries. Site status is shown where the registry gives one.
CZ007
Litoměřice, Czechia
CZ006
Lnáře, Czechia
CZ005
Prague, Czechia
CZ004
Prague, Czechia
CZ001
Ústí nad Labem, Czechia
EE002
Pärnu, Estonia
EE004
Tallinn, Estonia
EE005
Tallinn, Estonia
EE001
Võru, Estonia
EE003
Vorumaa, Estonia
HU004
Budapest, Hungary
HU002
Budapest, Hungary
LV003
Daugavpils, Latvia
LV002
Jelgava, Latvia
LV001
Riga, Latvia
LV004
Sigulda, Latvia
LT002
Kaunas, Lithuania
LT003
Kaunas, Lithuania
PL015
Bełchatów, Poland
PL008
Bydgoszcz, Poland
PL006
Gdansk, Poland
PL011
Krakow, Poland
PL002
Leszno, Poland
PL010
Lodz, Poland
PL014
Lodz, Poland
PL004
Lublin, Poland
PL005
Lublin, Poland
PL013
Piekary Śląskie, Poland
PL003
Skorzewo, Poland
PL007
Starogard Gdański, Poland
PL012
Swicie n/Wisla, Poland
PL009
Szczecin, Poland
PL001
Torun, Poland
RU013
Rostov-on-Don, Russia
RU002
Saint Petersburg, Russia
RU005
Saint Petersburg, Russia
RU006
Saint Petersburg, Russia
RU001
Saint Petersburg, Russia
RU012
Saint Petersburg, Russia
RU003
Saint Petersburg, Russia
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.